Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Moffitt Cancer Center - Magnolia Campus
Tampa, Florida, United States
- Ochsner Clinic Foundation
New Orleans, Louisiana, United States
- Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, United States
- the Valley Hospital - Luckow Pavilion
Paramus, New Jersey, United States
- Mary Crowley Cancer Research
Dallas, Texas, United States
- Millennium Oncology
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Mar 2022
- Primary completion
- 3 Feb 2025
- Completion
- 3 Feb 2025
- Last update posted
- 3 Jun 2026
- Registered enrollment
- 5
- Registry id
- NCT05062980
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.